April 9 (Reuters) - CStone Pharmaceuticals 2616.HK:
FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR
CEO PURCHASED 560,000 SHARES FROM APRIL 2 TO 7 WITH PURCHASE PRICE PER SHARE RANGING FROM HKD2.26 TO HKD3.29
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))